Seagen Inc. is looking for a new CEO for the first time in more than 20 years just as its multi-product expansion strategy is gaining momentum. The company announced the resignation of longtime CEO and co-founder Clay Siegall on 16 May after a sudden leave of absence following domestic abuse allegations.
"While the investigation continues, the board and Dr. Siegall agreed it is in the best interests of Seagen and its stakeholders for him to resign at this time," the company said. Siegall co-founded the company as an antibody-drug conjugate (ADC) specialist in 1998 and led the company through its first US Food and Drug Administration approval in 2011 and more recently as it expanded its portfolio to multiple commercial assets
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
